Therapeutic-protein manufacturing is often optimized through productivity-centered objectives, although increased product formation can alter metabolic allocation, folding demand, molecular heterogeneity, biological activity, cellular stability, and process sensitivity. This article proposes the Therapeutic Cell-Factory Reconciliation Architecture, an original non-empirical framework that organizes these interdependencies without reducing performance to titer or a single composite score. The architecture represents the therapeutic cell factory through coupled host, resource-allocation, expression and secretory-processing, process, product-attribute, stability, and control states. Yield, molecular quality, biological function, and manufacturing robustness are treated as non-substitutable objectives whose relationships depend on host, molecule, culture phase, operating mode, process history, and the active constraint. Process coupling is incorporated by tracing how environmental conditions influence intracellular allocation, product processing, extracellular integrity, population stability, and disturbance response. Design rules distinguish persistent constraints suited to static engineering from phase-dependent constraints that may justify dynamic intervention. Measurement, state estimation, and an uncertainty-aware world model are positioned as hypothesis-organizing components rather than validated decision systems. Validation requires orthogonal cellular, process, molecular, functional, longitudinal, and perturbational evidence, prospective testing, and explicit transfer boundaries. The contribution is a platform architecture that connects cell engineering to product-centered manufacturing consequences while preserving distinctions among plausibility, evidence, prediction, intervention, and readiness. It is not a validated model, qualified control strategy, regulatory standard, or deployment-ready system.
IJPRAS
